BioMarin Pharma (BMRN) Tops Q2 EPS by 2c, FY Guidance Unchanged

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. AAPL
3. JNJ
4. META
5. NRIX
6. SUNS
7. SPY
8. SNDX
9. CRDO
10. OIG

Go back to BioMarin Pharma (BMRN) Tops Q2 EPS by 2c, FY Guidance Unchanged

BioMarin Announces Second Quarter 2015 Financial Results and Company Update

August 3, 2015 4:02 PM EDT

- In First Six Months of 2015 Vimizim Sales Top $104 million and Total BioMarin Revenue Grows 32% Y/Y - First Patients Enrolled in 4th Cohort of Phase 2 Study of Vosoritide for the Treatment of Achondroplasia

Financial Highlights ($ in millions, except per share data, unaudited)

  Three Months Ended June 30, Six Months Ended June 30,   2015 2014 % Change 2015 2014 % Change               Total BioMarin Revenue  $ 250.5  $ 191.8 31%  $ 453.8  $ 343.3 32% Vimizim Net Product Revenue  53.9  14.3 n.m.  104.5... More